In honor of March Madness, The Motley Fool's health-care team assembled their own bracket consisting of the 16 largest and best pharmaceutical and biotech stocks on the market. The series gets under way with a tough matchup between AbbVie (ABBV -4.58%), Abbott's recently spun-off pharmaceutical division, and Big Pharma giant GlaxoSmithKline (GSK 0.49%). To learn the bull and bear cases for each stock -- and to see which stock will move on to the Elite Eight -- watch the following video.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
You might be more interested in March Madness, but if you're a long-term investor, the first round of Market Madness will keep you on the edge of your seat.
David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.